Dako to Collaborate with Merck
News Jan 09, 2014
Dako announce today it has entered into a master framework agreement with Merck to develop companion diagnostic tests for oncology drugs currently in Merck’s development pipeline.
"Dako is relentless in its commitment to fighting cancer, together with our customers and pharma partners," said Jacob Thaysen, vice president and general manager for Agilent's Diagnostics and Genomics business. "With Dako’s wide experience in companion diagnostics and its expanded playing field as part of Agilent’s Life Sciences and Diagnostics Group, I see great potential in this new agreement. I warmly welcome Merck as our new partner."
The market for companion diagnostics is steadily growing, as personalized medicine may improve patient care and manage healthcare costs by targeting treatments to individuals more likely to benefit from specific therapies.
Dako collaborates with many top-tier pharma companies to develop companion diagnostics, with a record of successful long-term partnerships with companies such as Bristol-Myers Squibb and Genentech, a member of the Roche Group. Dako continues to attract new partners, most recently Eli Lilly, Pfizer and now Merck.
The financial terms of the master framework agreement were not disclosed.
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019
12th International Conference on Cancer Stem Cells and Oncology Research
Jul 18 - Jul 19, 2019
4th Annual Congress on Nanomedicine and Drug Delivery
Apr 04 - Apr 06, 2019